|
DE19906744A1
(de)
*
|
1999-02-18 |
2000-08-24 |
Martin Roecken |
Verfahren zur Herstellung antitumoraler Th1-Zellen
|
|
CA2368967A1
(en)
*
|
1999-04-09 |
2000-10-19 |
Biomira, Inc. |
Telomerase-specific cancer vaccine
|
|
DE19917195B4
(de)
*
|
1999-04-16 |
2006-09-28 |
Immatics Biotechnologies Gmbh |
Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
|
|
CA2383737C
(en)
*
|
1999-09-08 |
2011-01-18 |
Transgene S.A. |
Muc-1 derived peptides
|
|
GB9921337D0
(en)
*
|
1999-09-09 |
1999-11-10 |
Axis Genetics Plc |
Modified plant viruses
|
|
GB0007150D0
(en)
*
|
2000-03-24 |
2000-05-17 |
Lamellar Therapeutics Limited |
Immunotherapeutic methods and compositions
|
|
JP2004533421A
(ja)
*
|
2001-03-27 |
2004-11-04 |
バイオミラ，インコーポレイテッド |
Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
|
|
US7282222B2
(en)
|
2002-03-15 |
2007-10-16 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Methods and compositions for directing cells to target organs
|
|
ES2375992T3
(es)
*
|
2002-04-15 |
2012-03-08 |
Oncothyreon Inc. |
Glucolipopéptidos sintéticos como vacunas.
|
|
WO2004022590A2
(en)
*
|
2002-09-05 |
2004-03-18 |
Cell Center Cologne Gmbh |
Immunogenic muc1 glycopeptides
|
|
BR0314471A
(pt)
*
|
2002-10-10 |
2005-08-02 |
Us Dept Veterans Affairs |
Detecção, localização e estadiamento de tumores usando linfócitos ativados classificados dirigidos a um epitopo especìfico do tumor
|
|
US20050045205A1
(en)
*
|
2003-08-29 |
2005-03-03 |
Stach Steven R. |
Apparatus and method for cleaning printed circuit boards
|
|
GB0322448D0
(en)
|
2003-09-25 |
2003-10-29 |
Lamellar Therapeutics Ltd |
Using lamellar bodies to modify linear biological macro molecules
|
|
EP1697399B1
(en)
*
|
2003-12-12 |
2016-11-23 |
GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS |
A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
|
|
TWI395591B
(zh)
|
2004-04-01 |
2013-05-11 |
Oncothyreon Inc |
黏液性糖蛋白（ｍｕｃ-１）疫苗
|
|
WO2006050116A1
(en)
*
|
2004-11-02 |
2006-05-11 |
Biomedical Research Models, Inc. |
Methods of cancer treatment/prevention using cancer cell-specific surface antigens
|
|
US8871250B2
(en)
|
2005-06-28 |
2014-10-28 |
Oncothyreon Inc. |
Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
|
|
WO2010002478A2
(en)
|
2008-07-03 |
2010-01-07 |
University Of Georgia Research Foundation, Inc. |
Glycopeptide and uses thereof
|
|
CA2637600A1
(en)
|
2006-01-17 |
2007-07-26 |
Health Research, Inc. |
Heteroduplex tracking assay
|
|
RU2377994C1
(ru)
*
|
2008-05-21 |
2010-01-10 |
Леонид Валентинович Загребин |
Способ иммунореабилитации онкозаболеваний
|
|
US20100059084A1
(en)
*
|
2008-09-10 |
2010-03-11 |
Austin American Technology Corporation |
Cleaning and testing ionic cleanliness of electronic assemblies
|
|
BR112012028893A2
(pt)
|
2010-05-10 |
2017-12-12 |
Ascend Biopharmaceuticals Pty Ltd |
composições imunoestimuladoras e de vacina
|
|
EP2678005A4
(en)
|
2011-02-24 |
2015-06-10 |
Oncothyreon Inc |
GLUCOLOPOPEPTIDE MUC1-BASED VACCINE WITH AN ADJUVANS
|
|
EP2800762B1
(en)
|
2012-01-03 |
2018-01-03 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Native and agonist ctl epitopes of the muc1 tumor antigen
|
|
WO2014183823A1
(en)
|
2013-05-14 |
2014-11-20 |
Merck Patent Gmbh |
Method of treating lung cancer by vaccination with muc-1 lipopeptide
|
|
WO2015058831A1
(en)
|
2013-10-25 |
2015-04-30 |
Merck Patent Gmbh |
Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
|
|
ES2973548T3
(es)
|
2016-12-22 |
2024-06-20 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
US20200010528A1
(en)
|
2017-03-15 |
2020-01-09 |
Cue Biopharma, Inc. |
Methods for modulating an immune response
|
|
GB201812647D0
(en)
|
2018-08-03 |
2018-09-19 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Viral vectors and methods for the prevention or treatment of cancer
|
|
JP2022536581A
(ja)
*
|
2019-06-19 |
2022-08-18 |
キュー バイオファーマ， インコーポレイテッド |
多量体ｔ細胞調節性ポリペプチド及びその使用方法
|
|
WO2021231376A2
(en)
|
2020-05-12 |
2021-11-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2022056014A1
(en)
|
2020-09-09 |
2022-03-17 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
|